Valeant CEO touts R&D output with new dermatology approval

Carly Helfand

Less than two weeks after losing longtime acquisition target Allergan–which happily sold itself to Actavis to dodge 's hostile bid and the R&D cuts it feared would come along with it–the Canadian pharma is talking up the productivity of its own labs.

FiercePharma News

Share This Post

Related Articles

Leave a Reply

© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS